My understanding is they could if they wanted to, but they don't have any ARDS data until the trial is unblinded, which won't be until 2021 unless extreme efficacy occurs.
They could use the results to link TNFR1 with a reduction in inflammation once they have the results.
My understanding is they could if they wanted to, but they don't...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
-0.025(1.55%) |
Mkt cap ! $2.031B | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.62 | $1.57 | $6.345M | 3.987M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 44493 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 4159 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |